Kidney Cancer Research Summit | Conference

Leveraging Biology to Guide First-Line Treatment of Clear Cell RCC

July 14th 2023

Determining the appropriate front-line treatment pathway for patients with clear cell renal cell carcinoma may not always align with risk stratification features.

Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCC

July 14th 2023

Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.

Dr Ged on Interim Data With Olaparib in DNA Repair Gene–Mutated mRCC

July 14th 2023

Yasser Mohamed Ali Ged, MBBS, discusses the phase 2 ORCHID trial (NCT03786796).

Dr Choueiri on Trials in Progress in Advanced Renal Cell Carcinoma

July 14th 2023

Toni K. Choueiri, MD, discusses ongoing trials in advanced renal cell carcinoma.

Dr McDermott on the Ongoing LITESPARK-024 Trial in Pretreated Advanced RCC

July 14th 2023

David F. McDermott, MD, discusses the randomized phase 2 LITESPARK-024 trial (NCT05468697).

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14th 2023

Neoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

Adjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages

July 14th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis-free survival compared with placebo across The University of California Los Angeles Integrated Staging System–categorized subgroups of patients with clear cell renal cell carcinoma.

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC

July 14th 2023

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

Imaging Mass Cytometry May Identify Therapeutic Targets in ccRCC

July 13th 2023

The tumor-immune evasion cell networks in clear cell renal cell carcinoma may be captured and classified using imaging mass cytometry, an orthogonal approach with the potential for increased cost-efffectiveness and accuracy compared with single-cell RNA sequencing.